{"name":"Isarna Therapeutics GmbH","slug":"isarna-therapeutics-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AP 12009 10 µM","genericName":"AP 12009 10 µM","slug":"ap-12009-10-m","indication":"Glioblastoma","status":"phase_2"},{"name":"AP 12009 80 µM","genericName":"AP 12009 80 µM","slug":"ap-12009-80-m","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AP 12009","genericName":"AP 12009","slug":"ap-12009","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AP 12009","genericName":"AP 12009","slug":"ap-12009","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AP 12009 10 µM","genericName":"AP 12009 10 µM","slug":"ap-12009-10-m","phase":"phase_2","mechanism":"AP 12009 is an antisense oligonucleotide that inhibits transforming growth factor-beta 2 (TGF-β2) expression to reduce immunosuppression and promote anti-tumor immunity.","indications":["Glioblastoma","Pancreatic cancer"],"catalyst":""},{"name":"AP 12009 80 µM","genericName":"AP 12009 80 µM","slug":"ap-12009-80-m","phase":"phase_2","mechanism":"AP 12009 80 µM is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNR0IyS3hKbkRhSzlOZXFMZzA5TVBtZWVtbVd1cG9KR0Q3WGZxMkpGSHR0VThNdXp6RFY1eEJESmxRQXNsR0tiRnJwa3llcnc4VVRZYS1GWFVjSUtQTTBlUWFKS1dvaFloZDNWdGxUOHBidTg5VkZnaVBHQ2JmSkJDTXlabHR3dkItZmc4a0dPUEZzZkowV3c?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com","headline":"Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPN202TUJ4Nm1xZ3AwUEFZbjh0cGl1NWc5WDJFLW03VHhlZnV0R28wOFR4UC0wNlJnSHV6WVY4aG9mdEtDZ1phbHdKWnUyaEhuTzUteERfdkpJdnA1S1VZVGp3TlpwcXhxeEJZeEttTzYwZlNKTHBtZ0dXVGhtSnZZeUs3bkxhTFpVZ2d0c3d5Mm83eGtlRmZJU3FseW5lYVhoeVBESV8zRW9fb1FPTk1jd1ZUb1dyeGlrTFBuMUhCcFBzTnI2azJadG9fWHlxVS1RX0Roc3NNbnIwS19aVEJXbE5zQUJBUHVwdDhhYlluVGZhcXlRVW1wak5xazJ2bFlNMmFzaV9oVENvOWRsTEJFdVRwc2Z3TURveTlIRkJRQXpLV3JWTldMRnBwZG1EdEJSVGdTVlhUVktvS3drSHFrTGFZUmhpcnpOUXl2cEN5OERFZVpE?oc=5","date":"2025-06-17","type":"trial","source":"GlobeNewswire","summary":"Oligonucleotides Clinical Trial Pipeline Analysis - GlobeNewswire","headline":"Oligonucleotides Clinical Trial Pipeline Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNR2NEczNLSl9lVGRoSEgyRm8wbWVDOU03dER1aVVCR3dMMHdLUzNPZHpCdzJzX1FCUzBvUkFHOXFZQlFsVEdMclFuZnRPcFdaS3lWSExockJSQ2g4cDR0WHhleG5wNERhUUEzSDlILXJCYUFSWFFHU3RtMk94cWJjRGJDdFJqX2JCS3c?oc=5","date":"2022-09-25","type":"pipeline","source":"EU-Startups","summary":"37 Top Biotechnology Startups and Companies in Munich - EU-Startups","headline":"37 Top Biotechnology Startups and Companies in Munich - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNTVN4S2JWMGE2VVJ4c0h1c0wtYTBSaWx2bXBxQmx6NF8xSVA1aElMdXRVakJnZ1lXenZGMFF2RWxQZ0NFTk55Mlh6M1ZVSHZtSktLNkpscE53V2RyTDZrbWx4YVdXSGFIN3BGaGpzTXBFajQ2aDRtNGFWWTFxQjNzdFVEY25Yb3U0dTQ5cWJwWGlZN1BhQXdlNjl6QVVaVFBmWUdyUXBBQk5JS3hn?oc=5","date":"2013-09-30","type":"pipeline","source":"Technology Networks","summary":"Antisense Pharma Changes Name to Isarna Therapeutics - Technology Networks","headline":"Antisense Pharma Changes Name to Isarna Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}